Trevi Therapeutics
NASDAQ: TRVINew Haven, US · Founded 2011 · Delaware corporation · 47 employees on LinkedIn · 3 known investors
Trevi Therapeutics is a clinical-stage biopharmaceutical company developing Haduvio (oral nalbuphine ER), an investigational therapy for chronic cough that targets the central and peripheral cough reflex arc. It is advancing the treatment for patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC).
Founders & leadership
Trevi Therapeutics was founded in 2011 by Jennifer L. Good, Thomas Sciascia, and Jennifer Good.
JL
Jennifer L. GoodCo-founder
TS
Thomas SciasciaCo-founder
JG
Jennifer GoodCo-Founder, President & CEO
LD
Lisa DelfiniExecutive
WF
William ForbesExecutive
MH
Michael HeffernanNamed on SEC filing
JC
James CassellaNamed on SEC filing
DC
Dominick ColangeloNamed on SEC filing
AV
Anne VanLentNamed on SEC filing
Board
EM
Edward MathersBoard director
DM
David MeekerBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$121.7M disclosed across 4 of 6 rounds · 2017–2026
▶$55MraisedApr 2022 · 12 investors · BiotechnologyRule 506(b)
▶$55MraisedApr 2022 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael HeffernanDirector
- Thomas SciasciaExecutive Officer
- David MeekerDirector
- James CassellaDirector
- Dominick ColangeloDirector
- Jennifer L. GoodExecutive Officer, Director
- William ForbesExecutive Officer
- Edward MathersDirector
- Anne VanLentDirector
- Lisa DelfiniExecutive Officer
- Offering amount
- $55M
- Amount sold
- $55M
- Sales commissions
- $3.3M
- Placement agents
- Needham & Company, LLC, Oppenheimer & Co. Inc., Aegis Capital Corp., Stifel, Nicolaus & Company, Incorporated
- First sale
- Apr 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3MraisedOct 2021 · 1 investors · BiotechnologyRule 506(b)
▶$3MraisedOct 2021 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Edward MathersDirector
- Michael HeffernanDirector
- Lisa DelfiniExecutive Officer
- James CassellaDirector
- Dominick ColangeloDirector
- Jennifer L. GoodExecutive Officer, Director
- Anne VanLentDirector
- William ForbesExecutive Officer
- Thomas SciasciaExecutive Officer
- David MeekerDirector
- Offering amount
- $3M
- Amount sold
- $3M
- First sale
- Oct 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$11.8MraisedOct 2021 · 1 investors · BiotechnologyRule 506(b)
▶$11.8MraisedOct 2021 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Anne VanLentDirector
- Dominick ColangeloDirector
- William ForbesExecutive Officer
- Jennifer L. GoodExecutive Officer, Director
- Edward MathersDirector
- James CassellaDirector
- Lisa DelfiniExecutive Officer
- David MeekerDirector
- Michael HeffernanDirector
- Thomas SciasciaExecutive Officer
- Offering amount
- $11.8M
- Amount sold
- $11.8M
- Sales commissions
- $709K
- Placement agents
- Stifel, Nicolaus & Company, Incorporated, Needham & Company, LLC
- First sale
- Oct 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$51.9MraisedSep 2018 · 18 investors · BiotechnologyRule 506(b)
▶$51.9MraisedSep 2018 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Thomas R. SciasciaExecutive Officer
- Michael HeffernanDirector
- Mette Kirstine AggerDirector
- Ed MathersDirector
- Chris SeiterExecutive Officer
- Annie MitsakDirector
- Jennifer L. GoodExecutive Officer, Director
- Eran NadavDirector
- David MeekerDirector
- Offering amount
- $61.9M
- Amount sold
- $51.9M
- First sale
- Jul 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 6
by search overlap
Seeking Alpha20 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Robinhood19 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
TradingView19 shared keywordsTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
TipRanks18 shared keywordsFinancial analysis and stock research platform.
Simply Wall St15 shared keywordsSimply Wall St is a stock analysis platform that provides portfolio insights, stock discovery tools, and market alerts for individual investors. The service offers institutional-grade financial data visualization and analysis across 120,000 global stocks.
StockTwits14 shared keywordsStocktwits is a social platform for investors and traders to share market news, discussions, sentiment polls, and live financial content. It aggregates breaking market news, equity coverage, and community discussions around individual stocks and crypto.
Companies competing with Trevi Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Trevi Therapeutics do?
- Trevi Therapeutics is a clinical-stage biopharmaceutical company developing Haduvio (oral nalbuphine ER), an investigational therapy for chronic cough that targets the central and peripheral cough reflex arc. It is advancing the treatment for patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC).
- Who founded Trevi Therapeutics?
- Trevi Therapeutics was founded by Jennifer L. Good, Thomas Sciascia, Jennifer Good in 2011.
- Who are Trevi Therapeutics's investors?
- Trevi Therapeutics's investors include APERTURE Venture Partners, Frazier Life Sciences, New Enterprise Associates (NEA).
- How much funding has Trevi Therapeutics raised?
- Trevi Therapeutics has disclosed $121.7M raised across 4 of its 6 known rounds.
- Where is Trevi Therapeutics headquartered?
- Trevi Therapeutics is headquartered in New Haven, US.